

16C3
5/23/01

RECEIVED

AUG 29 2001

TECH CENTER 1600/2900

1624
#18
8/1/01
C. Style

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.



DATE: August 23, 2001

BOX NON-FEE AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Louis S. Kucera <i>et al.</i>	: Group Art Unit: 1624
		:
		:
Appln. No.:	09/412,539	: Examiner: B. Coleman
		:
Filed:	October 4, 1999	:
		:
For:	LIPID ANALOGS FOR TREATING VIRAL INFECTIONS	: Attorney Docket
		: No. 0044317U3
		: 053665-5005-02-US

RESPONSE

This Response is in regards to the Office Action dated May 23, 2001 (Paper No. 17), sent in connection with the above-referenced application. This Response is timely filed.

REMARKS

Claims 56-71, 95, 96 and 101 are pending and stand rejected in the Office Action under 35 U.S.C. § 112, second paragraph. Claims 56-71, 96 and 101 also stand rejected under 35 U.S.C. § 112, first paragraph.

Rejection Under 35 U.S.C. § 112, Second Paragraph

Claims 56-71, 95, 96 and 101 stand rejected under 35 U.S.C. § 112, second paragraph, as indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention. The Office Action indicates it is not clear how a hydrogen atom at the 3 position would embrace the specific moiety of Formula VII when Formula VII is cytosine. Applicants respectfully traverse the rejection.